{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T12:10:53Z","timestamp":1763295053127},"reference-count":14,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,10,30]],"date-time":"2009-10-30T00:00:00Z","timestamp":1256860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> KOGENATE<jats:sup>\u00ae<\/jats:sup> Bayer (rFVIII\u2010FS) with Bio\u2010Set<jats:sup>\u00ae<\/jats:sup> is designed to prevent patient contact with exposed needles during recombinant factor VIII reconstitution. This postmarketing surveillance study evaluated patient satisfaction before and after switching to the new Bio\u2010Set reconstitution method. Male children and adults with haemophilia A were enrolled from nine European countries. A preference questionnaire was administered to patients after Bio\u2010Set training and at the end of the observation period (\u226520 exposure days or 3\u2003months). Physician assessments of patient compliance and satisfaction were conducted at the end of the observation period. Patients (<jats:italic>N<\/jats:italic>\u2003=\u2003306) received a mean\u2003\u00b1\u2003SD of 28\u2003\u00b1\u200323 infusions of rFVIII\u2010FS with Bio\u2010Set. A majority of patients (82%) preferred the Bio\u2010Set method, with domain scores for ease of use, safety from needlesticks, and speed of reconstitution being highest after training and at the end of the observation period. The Bio\u2010Set method received higher mean scores than previous reconstitution methods for worry\/safety and ease\/confidence domains at both time points. Physician\u2010reported patient compliance with the Bio\u2010Set method was similar or greater compared with the previous method for 94% of the patients, with physicians reporting that 92% of the patients were satisfied or very satisfied with Bio\u2010Set. Thirteen adverse events (AEs) occurred in nine patients, and five serious AEs occurred in five patients; none was related to rFVIII\u2010FS. No <jats:italic>de novo<\/jats:italic> or recurrent inhibitor development was observed during the observation period. rFVIII\u2010FS with Bio\u2010Set was well tolerated and well accepted by haemophilia A patients, which may improve treatment compliance.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2009.02113.x","type":"journal-article","created":{"date-parts":[[2009,10,30]],"date-time":"2009-10-30T10:14:10Z","timestamp":1256897650000},"page":"66-71","source":"Crossref","is-referenced-by-count":13,"title":["Postmarketing surveillance study of KOGENATE<sup>\u00ae<\/sup> Bayer with Bio\u2010Set<sup>\u00ae<\/sup> in patients with haemophilia A: evaluation of patients\u2019 satisfaction after switch to the new reconstitution system"],"prefix":"10.1111","volume":"16","author":[{"given":"N.","family":"VIDOVIC","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"MUSSO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"KLAMROTH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. M.","family":"ENRIQUEZ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"ACHILLES","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,12,29]]},"reference":[{"key":"e_1_2_7_2_2","unstructured":"World Federation for Hemophilia.Guidelines for the Management of Hemophilia.2005. Available at:http:\/\/www.wfh.org\/2\/docs\/Publications\/Diagnosis_and_Treatment\/Gudelines_Mng_Hemophilia.pdf(last accessed on 18 September 2009)."},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01501.x"},{"key":"e_1_2_7_4_2","unstructured":"National Hemophilia Foundation.MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). MASAC Document 179 Revised November 2007. Available at:http:\/\/www.hemophilia.orgNHFWebMainPgsMainNHF.aspx?menuid=57&contentid=1007(last accessed on 18 September 2009)."},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2001.00534.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01189.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.7748\/paed.18.10.19.s16"},{"key":"e_1_2_7_8_2","volume-title":"Children\u2019s opinions of transfer devices for reconstitution of factor VIII\/IX","author":"Hemophilia 2006 World Congress"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.3928\/08910162-20080101-02"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-008-1011-8"},{"key":"e_1_2_7_11_2","volume-title":"KOGENATE\u00ae Bayer. Summary of Product Characteristics","author":"Bayer HealthCare AG","year":"2007"},{"key":"e_1_2_7_12_2","first-page":"63","article-title":"Evaluation of user preference for a needleless factor VIII delivery device for haemophilia patients","volume":"8","author":"Butler R","year":"2004","journal-title":"J Outcomes Res"},{"key":"e_1_2_7_13_2","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1182\/blood.V104.11.5303.5303","article-title":"Time and cost savings with Bio\u2010Set device in reconstituting FVIII concentrate [abstract]","volume":"104","author":"Brewster J","year":"2004","journal-title":"Blood"},{"key":"e_1_2_7_14_2","first-page":"PO965","article-title":"Patients\u2019 satisfaction with a new reconstitution system for KOGENATE Bayer: initial German experiences [abstract]","volume":"12","author":"Goldmann G","year":"2006","journal-title":"Haemophilia"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2009.02113.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2009.02113.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T03:54:34Z","timestamp":1698638074000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2009.02113.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,29]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1111\/j.1365-2516.2009.02113.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2009.02113.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,29]]}}}